Market News AIOpen the app

NeOnc Technologies' CEO bought 30,000 shares and shared better results from the NEO100 study.

TrialRead the original at SEC EDGAR
Good for NTHI

NeOnc reported that NEO100 responses rose to 3 of 24 patients, lifting the response rate from 8.3% to 12.5%. This is encouraging, but the small early study and planned FDA discussion do not show that the drug is approved or proven.

NTHI · NeOnc Technologies Holdings, Inc.

AI read · Good for NTHI

The AI's read

A higher response rate gives NeOnc a stronger early sign that NEO100 may help patients with brain cancer. Still, this is a small Phase 2a group, and the FDA meeting is only to discuss a possible approval path and a proposed later trial. The drug remains under study, so the result is promising but not proof it works.

Get alerts for NTHI

Follow NeOnc Technologies Holdings, Inc. (NTHI) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NTHI
Free on the App Store and Google Play, or on the web.